Acute cytogenetic effects of antineoplastic drugs on peripheral blood lymphocytes in cancer patients: Chromosome aberrations and micronuclei

Tumori

Volumn 88, Issue 4, 2002, Pages 300-312

  Kopjar, Nevenka ^a   Garaj Vrhovac, Vera ^a   Milas, Ivan ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Antineoplastic drugs; Cytogenetic biomarkers; DAPI; Giemsa; Silver staining

Indexed keywords

ADRIABLASTINA RD; BLEOMICINA; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; FOLINATE CALCIUM; LEUCOVORIN 30; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; ARTICLE; BREAST CANCER; CHEMICAL MUTAGENESIS; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENOTOXICITY; GIEMSA STAIN; HODGKIN DISEASE; HUMAN; HUMAN CELL; MALE; MICRONUCLEUS; NONHODGKIN LYMPHOMA; SILVER STAINING;

EID: 0036658209     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800412     Document Type: Article

References (55)

1. International Agency for Research on Cancer (IARC): Some antineoplastic and immunosuppressive agents. IARC Monographs on the evaluation of carcinogenic risks to humans, 26: 411, 1981.
2. International Agency for Research on Cancer (IARC): Some antiviral and antineoplastic drugs and other pharmaceutical agents. IARC Monographs on the evaluation of carcinogenic risks to humans, 76: 522, 2000.
3. Othman OEMS: Cytogenetic effect of anticancer drug epirubicin on Chinese hamster cell line in vitro. Mutat Res, 468: 109-115, 2000.
4. Hannson J: Inherited defects in DNA repair and susceptibility to DNA-damaging agents. Toxicol Lett, 64/65: 141-148, 1992.
5. Surallés J, Puerto S, Ramírez MJ, Creus A, Marcos R, Mullenders LHF, Natarajan AT: Links between chromatin structure, DNA repair and chromosome fragility. Mutat Res, 404: 39-44, 1998.
6. Ribas M, Miró R, Gelabert A, Egozcue J: Chromosome instability in lymphocytes from two patients affected by three sequential primary cancers: the role of fragile sites. Cancer Genet Cytogenet, 110: 133-135, 1999.
7. Abdallah JM, Lombardi DP, Kirsch IR: Genetic instability in patients with Hodgkin's disease undergoing chemotherapy. J Clin Invest, 96: 2744-2747, 1995.
8. Çeçener G, Egeli Ü, Tasdelen I, Tunca B, Duman H, Kizil A: Common fragile site expression and genetic predisposition to breast cancer. Teratog Carcinog Mutagen, 18: 279-291, 1998.
9. Gebhart E, Romahn R, Schneider A, Hoffmann M, Rau D, Tittelbach H: Cytogenetic studies in lymphocytes of patients with rectal cancer. Environ Health Perspect, 101: 169-175, 1993.
10. Wu XF, Spitz MR, Delclos GL, Connor TH, Zhao Y, Siciliano MJ, Hsu TC: Survival of cells with bleomycin-induced chromosomal lesions in the cultured lymphocytes of lung cancer patients. Cancer Epidemiol Biomarkers Prev, 5: 527-532, 1996.
11. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas MD Anderson Cancer Center experience. J Clin Oncol, 14: 2722-2730, 1996.
12. Kelsey KT, Caggana M, Mauch PM, Coleman CN, Clark JR, Liber HL: Mutagenesis after cancer therapy. Environ Health Perspect, 101: 177-184, 1993.
13. Pratt CB, Meyer WH, Luo X, Cain AM, Kaste SC, Pappo AS, Rao BN, Fleming ID, Jenkins JJ: Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer, 80: 960-965, 1997.
14. Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land VJ, Miser J, Shuster J, Vena D: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol, 17: 569-577, 1999.
15. Aronson MM, Miller RC, Hill RB, Nichols WW, Meadows AT: Acute and long-term cytogenetic effects of treatment in childhood cancer. Sister-chromatid exchanges and chromosome aberrations. Mutat Res, 92: 291-307, 1982.
16. Celotti L, Biasin R, Ferraro P, Fiorentino M: Effects of in vivo exposure to antineoplastic drugs on DNA repair and replication in human lymphocytes. Mutat Res, 245: 217-222, 1990.
17. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst, 85: 25-31, 1993.
18. Perry JR, Brown MT, Gockerman JP: Acute leukemia following treatment of malignant glioma. J Neuro-Oncol, 40: 39-46, 1998.
19. Sarto F, Tomanin R, Giacomelli L, Canova A, Raimondi F, Ghiotto C, Fiorentino MV: Evaluation of chromosomal aberrations in lymphocytes, oral mucosa and hair root cells of patients under antiblastic therapy. Mutat Res, 228: 157-169, 1990.
20. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst, 87: 524-530, 1995.
21. Kevekordes S, Gebel TW, Hellwig M, Dames W, Dunkelberg H: Human effect monitoring in cases of occupational exposure to antineoplastic drugs: a method comparison. Occup Environ Med, 55: 145-149, 1998.
22. Carbonell E, Demopoulos NA, Stefanou G, Psaraki K, Parry EM, Marcos R: Cytogenetic analysis in peripheral lymphocytes of cancer patients treated with cytostatic drugs: results from an EC Collaborative Study. Anti-Cancer Drug, 7: 514-519, 1996.
23. Hagmar L, Bonassi S, Strömberg U, Brogger A, Knudsen LE, Norppa H, Reuterwall C, The European Study Group on Cytogenetic Biomarkers and Health: Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res, 58: 4117-4121, 1998.
24. Tucker JD, Preston RJ: Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat Res, 365: 147-159, 1996.
25. Collins A, Dusinska M, Franklin M, Somorovska M, Petrovska H, Duthie S, Fillion L, Panayiotidis M, Raslova K, Vaughan N: Comet assay in human biomonitoring studies - reliability, validation, and applications. Environ Mol Mutagen, 30: 139-146, 1997.
26. Kopjar N, Garaj-Vrhovac V: Application of the alkaline comet assay in human biomonitoring for genotoxicity: a study on Croatian medical personnel handling antineoplastic drugs. Mutagenesis, 16: 71-78, 2001.
27. Olive PL: The comet assay in clinical practice. Acta Oncol, 38: 839-844, 1999.
28. Vaghef H, Nygren P, Edling C, Bergh J, Hellman B: Alkaline single-cell gel electrophoresis and human biomonitoring for genotoxicity: a pilot study on breast cancer patients undergoing chemotherapy including cyclophosphamide. Mutat Res, 395: 127-138, 1997.
29. Carrano AV, Natarajan AT: Considerations for population monitoring using cytogenetic techniques. Mutat Res, 204: 379-406, 1988.
30. Fenech M, Morley AA: Measurement of micronuclei in lymphocytes. Mutat Res, 147: 29-36, 1985.
31. Schweizer D: Counterstain-enhanced chromosome banding. Hum Genet, 57: 1-14, 1981.
32. Howell WM, Black DA: Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method. Experientia, 36: 1014-1015, 1980.
33. Cochón AC, Aldonatti C, San Martín De Viale LC, Wainstok De Calmanovici R: Evaluation of the porphyrogenic risk of antineoplastics. J Appl Toxicol, 17: 171-177, 1997.
34. Carrano AV: Chromosomal alterations as markers of exposure and effect. J Occup Med, 28: 1112-1116, 1986.
35. Fenech M: Important variables that influence base-line micronucleus frequency in cytokinesis-blocked lymphocytes - a biomarker for DNA damage in human populations. Mutat Res, 404: 155-165, 1998.
36. Jacobson-Kram D, Albertini RJ, Branda RF, Falta MT, Iype PT, Kolodner K, Liou SH, McDiarmid MA, Morris M, Nicklas JA, O'Neil JP, Poirier MC, Putman D, Strickland PT, Williams JR, Xiao S: Measurement of chromosomal aberrations, sister chromatid exchanges, hprt mutations, and DNA adducts in peripheral lymphocytes of human populations at increased risk for cancer. Environ Health Perspect, 101 (Suppl 3): 121-125, 1993.
37. Kirschvolders M, Elhajouji A, Cundari E, Vanhumelem P: The in vitro micronucleus test - a multiendpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res, 392: 19-30, 1997.
38. Anwar WA: Cytogenetic monitoring of human populations at risk in Egypt: role of cytogenetic data in cancer risk assessment. Environ Health Persp, 96: 91-95, 1991.
39. Norppa H, Luomahaara S, Heikanen H, Roth S, Sorsa M, Renzi L, Lindholm C: Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogenes and clastogens. Environ Health Perspect, 101 (Suppl 3): 139-143, 1993.
40. Venkatachalam P, Solomon FD, Mohankumar MN, Prabhu BK, Gajendiean N, Kathiresan A, Jeevanram RK: Higher frequency of dicentrics and micronuclei in peripheral blood lymphocytes of cancer patients. Mutat Res, 425: 1-8, 1999.
41. Rothfuss A, Schütz P, Bochum S, Volm T, Eberhardt E, Kreienberg R, Vogel W, Speit G: Induced micronucleus frequencies in peripheral blood lymphocytes as a screening test for carriers of a BRCA 1 mutation in breast cancer families. Cancer Res, 60: 390-394, 2000.
42. Patel J, Rideout D: Synergism and antagonism in cancer chemotherapy. Cancer J, 5: 254-266, 1992.
43. Noviello E, Aluigi MG, Cimoli G, Rovini E, Mazzoni A, Parodi S, De Sessa F, Russo P: Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks. Mutat Res, 311: 21-29, 1994.
44. Anderson D, Bishop JB, Colin Garner R, Ostrosky-Wegman P, Selby PB: Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res, 330: 115-181, 1995.
45. González-Cid M, Cuello MT, Larripa I: Comparison of the aneugenic effect of vinorelbine and vincristine in cultured human lymphocytes. Mutagenesis, 14: 63-66, 1999.
46. Garaj-Vrhovac V, Kopjar N: Micronuclei in cytokinesis-blocked lymphocytes as an index of occupational exposure to antineoplastic drugs. Radiol Oncol, 32: 385-392, 1998.
47. Tonfanelli S, Stanyon R, Agostini M, Franceschi MG, Paoli G: Variability of DA/DAPI and C-heterochromatic regions: a population study. Hum Biol, 65: 635-646, 1993.
48. Derenzini M, Sirri V, Trere D: Nucleolar organizer regions in tumor cells. Cancer J, 7: 71-77, 1994.
49. Klobusická M, Babusiková O: The relationship between argyrophilic proteins and some immunophenotypic markers in acute leukemia cells. Neoplasma, 44: 356-360, 1997.
50. Pedrazzini E, Slavutsky IR: Ag-NOR staining and satellite association in bone marrow cells from patients with mycosis fungoides. Hereditas, 123: 9-15, 1995.
51. Surrallés J, Catalan J, Creus A, Norppa H, Xamena N, Marcos R: Micronuclei induced by alachlor, mitomycin-C and vinblastine in human lymphocytes: presence of centromeres and kinetochores and influence of staining technique. Mutagenesis, 10: 417-423, 1995.
52. Wu XF, Zhao Y, Kemp BL, Amos CI, Siciliano MJ, Spitz MR: Chromosome 5 aberrations and genetic predisposition to lung cancer. Int J Cancer, 79: 490-493, 1998.
53. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C: Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Canc Res Clin Oncol, 124: 207-214, 1998.
54. Greene MH, Harris EL, Gersherson DM: Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med, 105: 360-367, 1986.
55. Haas JF, Kittleman B, Mehnert WH, Staneczek W, Möhner M: Risk of leukaemia in ovarian tumor and breast cancer patients following treatment by cyclophosphamide. Br J Cancer, 55: 213-218, 1987.